RxDoctor Payments Data

Alana Williams, MD

Urogynecology and Reconstructive Pelvic Surgery · Albuquerque, NMNPI 1124106323

Payments from drug & device makers

$12,915in general payments, 2019–2025

Across 186 payments — averaging $69.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Medtronic$5K
  • Axonics, Inc.$642
  • AbbVie$458
  • Merz North America, Inc.$316
  • Astellas Pharma US Inc$301
  • plus $1K from 24 others

What the payments were for

  • Speaking & faculty fees$4,16032%
  • Travel & lodging$1,37411%
  • Food & beverage$4,26833%
  • Education$3,02723%
  • Gifts$861%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$60,849
Medicare patients
237
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron131$149,812
GemtesaVibegron21$23,638
BotoxOnabotulinumtoxina12$13,101
Estradiol212$11,181
PremarinEstrogens, Conjugated16$8,118
Mirabegron ErMirabegron11$7,391
Estradiol (Twice Weekly)Estradiol49$3,598
ProgesteroneProgesterone, Micronized35$1,907
Clobetasol Propionate30$1,861
DottiEstradiol17$1,628
Solifenacin Succinate42$1,443
Heparin SodiumHeparin Sodium,porcine17$866
Hydroxyzine Hcl13$704
ValacyclovirValacyclovir Hcl11$635
NitrofurantoinNitrofurantoin Macrocrystal20$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$301$149,812131 claims
Sumitomo Pharma America, Inc.Gemtesa$48$23,63821 claims
AbbVieBotox$458$13,10112 claims
PfizerPremarin$141$8,11816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in New Mexicoon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Albuquerque

Where these figures come from

Is this you, or does something look wrong? →